Shares in antimicrobial technologies group Byotrol jumped on Wednesday morning after it updated the market on its year of significant investment in both the business itself and its technologies. A sale by AIM-quoted Byotrol to Solvay of its Actizone patents and intellectual property in return for "substantial" cash payments over the next two financial years, ongoing royalty payments and a further payment in early 2022, should see sales exceed certain targets in 2021.
